Is Ozempic to blame for the slowdown in salty snack sales? Here’s the verdict
Investors who worry that rising GLP-1 drug usage has impaired salty snack sales might be pointing the finger at the wrong culprit.
Investors who worry that rising GLP-1 drug usage has impaired salty snack sales might be pointing the finger at the wrong culprit.
